Moderna Lifts 2026 Revenue Growth Outlook to 15%–25% After Q3 Sales Rise 29%
Moderna, Inc. raised its 2026 expected revenue growth to 15% to 25% from a prior outlook of up to 10% after reporting third-quarter revenue of $1.3 billion, up 29% from $1.0 billion a year earlier, according to an 8-K furnished Friday.
GAAP net income was $162 million, or $0.38 per diluted share, compared with a net loss of $200 million, or $0.51 per share, a year earlier. U.S. revenue was $780 million and international revenue was $533 million, led by higher COVID vaccine sales under long-term government partnerships.
Outlook and balance sheet
Moderna improved its 2026 GAAP operating expense outlook by an estimated $0.2 billion from its previous estimate, cutting expected research and development expenses to an estimated $2.7 billion from an estimated $2.9 billion. Selling, general and administrative expenses are still expected at an estimated $1.0 billion. Year-end 2026 cash and investments are now expected at $8.1 billion to $8.3 billion, up from a prior outlook of $4.7 billion to $5.2 billion, reflecting operations and convertible notes proceeds. Cash, cash equivalents and investments were $8.0 billion at Sept. 30, 2026.
CEO Stéphane Bancel pointed to U.S. FDA approval of mFLUSIVA, Moderna’s fifth approved product globally, and positive Phase 3 data for intismeran in melanoma.
By the numbers
- Q3 revenue: $1.3 billion, up 29%
- Q3 GAAP diluted EPS: $0.38
- 2026 revenue growth outlook: 15% to 25%
- Expected year-end cash and investments: $8.1 billion to $8.3 billion
Sources
- Moderna Form 8-K with third-quarter 2026 earnings release (Exhibit 99.1), filed Nov. 6, 2026 (accession 0001682852-26-000194)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.